检索结果-南通市图书馆

Journal of Environmental Sciences 2017年第6期29卷 254-262页

作者： Qingpeng Meng Hong Chen junzhong lin Zhang lin Junliang Sun Key Laboratory of Orogenic Belts and Crustal Evolution Ministry of EducationSchool of Earth and Space SciencesPeking UniversityBeijing 100871China Berzelii Center EXSELENT on Porous Materials Department of Materials and Environmental ChemistryStockholm UniversitySE-106 91 StockholmSweden School of Environment and Energy South China University of TechnologyThe Key Lab of Pollution Control and Ecosystem Restoration in Industry Clusters(Ministry of Education)Guangzhou Higher Education Mega CenterGuangzhou 510006China College of Chemistry and Molecular Engineering Peking UniversityBeijing100871China

High quality zeolite A was synthesized through a hydrothermal process using alkaline- assisted pre-activated halloysite mineral as the alumina and silica source. The synthesis conditions employed in this study were finely tuned by varying the activating temperature, sodium hydroxide content, water content and Si/A1 ratio. The obtained zeolite A showed excellent adsorption properties for both single metal cation solutions and mixed cation solutions when the concentrations of the mixed cations were comparable with those in polluted natural river water and industrial wastewater. High adsorptive capacities for Ag （123.05 rag/g） and Pb2＋（227.70 mg/g） were achieved using the synthesized zeolite A. This observation indicates that the zeolite A synthesized from alkaline-assisted pre-activated halloysite can be used as a low-cost and relatively effective adsorbent to purify heavy metal cation polluted natural river water and industrial wastewater.

关键词： ZeoliteHeavy metalRiver waterIndustrial wastewater

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer:a Chinese single-center experience

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 536-547页

作者： Jianhong Peng Weihao Li Rongxin Zhang junzhong lin Jinghua Tang Yongshan Wen Zhenhai Lu Xiaojun Wu Zhizhong Pan Department of Colorectal Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhouGuangdong 510060P.R.China

Background:A fixed 8-cycle oxaliplatin and capecitabine(XELOX)regimen has been the standard adjuvant therapy for patients with stage III colon ***,completing the full-cycle of oxaliplatin is often associated with severe *** spare patients from the toxic effects,without comprising the required efficacy,we evaluated the safety and efficacy of a modified XELOX(mXELOX)adjuvant chemotherapy regimen with 6 cycles of oxaliplatin and a full cycle of ***:We retrospectively analyzed 330 eligible patients with stage III colon cancer who underwent cura-tive tumor resection followed by mXELOX,standard XELOX or unfinished XELOX adjuvant chemotherapy between December 2007 and April *** prognostic factors were investigated and their disease-free survival(DFS)and overall survival(OS)rates were also determined and compared among the different regimen ***:Compared with the standard XELOX group,the mXELOX group had lower total incidence rates of neuro-toxicity(39.3%vs.76.2%,P<0.001),leucopenia(53.6%vs.69.8%,P=0.017)and thrombocytopenia(38.1%vs.56.3%,P=0.011).The standard XELOX and mXELOX adjuvant chemotherapy regimens presented with comparable 3-year DFS rates(86.3%vs.89.2%;P=0.838)and 3-year OS rates(92.7%vs.97.6%;P=0.227).Compared to unfinished XELOX chemotherapy,the oncologic benefits of the mXELOX regimen were greater for patients with T4 tumors(3-year DFS:Hazard ratio[HR],2.184;95%confidence interval[CI],1.051-4.540;P=0.036;3-year OS:HR,4.529;95%CI 1.245-16.479;P=0.022)and for high-risk patients(3-year DFS:HR,1.962;95%CI 0.964-3.993;P=0.044;3-year OS:HR,4.193;95%CI 1.182-14.874;P=0.026).Conclusions:The mXELOX adjuvant chemotherapy presented a comparable survival benefit and lower incidence of toxicity than standard XELOX *** could be an alternative treatment for high-risk patients with operated stage III colon cancer.

关键词： Colon cancer Adjuvant chemotherapy Oxaliplatin Capecitabine XELOX Efficacy Safety

Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2018年第1期38卷 319-328页

作者： Zhizhong Pan Jianhong Peng junzhong lin Gong Chen Xiaojun Wu Zhenhai Lu Yuxiang Deng Yujie Zhao Qiaoqi Sui Desen Wan Department of Colorectal Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer Medicine651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China

Background:Although colorectal oligometastases to the liver can potentially be cured with aggressive local abla-tion,the efficacy of adjuvant chemotherapy(ACT)for such metastasis remains *** present study explored the effects of ACT on patients with colorectal liver oligometastases(CLO)after curative resections and aimed to iden-tify patients who could benefit from ***:We retrospectively analyzed 264 eligible patients with CLO who underwent curative resection between September 1999 and June ***-free survival(RFS)and overall survival(OS)were analyzed using the Kaplan-Meier method and log-rank test;prognostic factors were a by Cox regression ***:Among 264 patients,200(75.8%)patients received ACT and 64(24.2%)did not receive *** two groups did not significantly differ in clinicopathologic characteristics,and had comparable 3-year OS and RFS rates(RFS:42.1%vs.45.7%,P=0.588;OS:69.7%vs.62.7%,P=0.446)over a median follow-up duration of 35.5 months,irrespective of preoperative *** markedly improved 3-year OS in high-risk patients with Memorial Sloan-Kettering Cancer Center clinical risk scores(MSKCC-CRS)of 3-5(68.2%vs.33.8%,P=0.015),but presented no additional benefit in patients with MSKCC-CRS of 0-2(72.2%vs.78.6%,P=0.834).In multivariate analysis,ACT was independently associated with improved OS in patients with MSKCC-CRS of ***:ACT might offer a prognostic benefit in high-risk patients with CLOs after curative liver resection,but not in low-risk ***,patients’risk status should be determined before ACT administration to optimize postoperative therapeutic strategies.

关键词： Colorectal cancer Oligometastases Adjuvant chemotherapy Liver resection Benefit

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国大学城建设如何走出两难困境

辽宁教育研究 2005年第8期 35-38页

作者：林隽中深圳大学广东深圳518060

应用科学发展观分析中国大学城建设的历史和现状,提出高等教育在宏观决策上要遵循市场经济规律,走可持续发展之路;在微观上要妥善处理各种矛盾和利益间的关系,实现大学城与周边地区的和谐互动,使大学城建设尽快走出困境,为建立和谐社会... 详细信息

应用科学发展观分析中国大学城建设的历史和现状,提出高等教育在宏观决策上要遵循市场经济规律,走可持续发展之路;在微观上要妥善处理各种矛盾和利益间的关系,实现大学城与周边地区的和谐互动,使大学城建设尽快走出困境,为建立和谐社会做出贡献。

关键词：高等教育大学城建设科学发展观和谐社会

在线全文

学校读者我要写书评

暂无评论

高校物业管理的风险初探

开放导报 2005年第6期 107-109页

作者：林隽中深圳大学深圳518060

高校物业管理除了行业的一般性风险外,还面临着一些日益凸显出来的特殊性风险。这些风险关系到高校物业管理公司的生存和发展。本文从政治风险、体制风险、市场风险和法律风险等四个方面进行了描述和分析,以引起业界的关注与探讨。

关键词：高校物业管理政治风险体制风险市场风险法律风险

FBXW7βloss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第6期8卷 3123-3143页

作者： Wenxia Wei Baifu Qin Weijie Wen Boyu Zhang Haidan Luo Yuzhi Wang Hui Xu Xiaoshan Xie Sicheng Liu Xin Jiang Mengan Wang Qin Tang Jiayu Zhang Runxiang Yang Zongmin Fan Haiwen Lyu junzhong lin Kai Li Mong-Hong Lee Guangdong Provincial Key laboratory of Colorectal and Pelvic Floor Disease The Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou510655China Guangdong Institute of Gastroenterology Guangzhou510655China Second Department of Medical Oncology The Third Affiliated Hospital of Kunming Medical UniversityKunming650118China Guangzhou Institute of Pediatrics Guangzhou Women and Children’s Medical CenterGuangzhou Medical UniversityGuangzhou510623China Department of Colorectal Surgery Cancer CenterSun Yat-sen UniversityGuangzhou510060China Department of Oncology The Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou510655China

Continuous de novo fatty acid synthesis is required for the biosynthetic demands of ***7 is a highly mutated gene in CRC,but its biological functions in cancer are not fully ***,we report that FBXW7β,a FBXW7 isoform located in the cytoplasm and frequently mutated in CRC,is an E3 ligase of fatty acid synthase(FASN).Cancer-specific FBXW7βmutations that could not degrade FASN can lead to sustained lipogenesis in ***9 signalosome subunit 6(CSN6),an oncogenic marker of CRC,increases lipogenesis via interacting with and stabilizing *** studies show that CSN6 associates with both FBXW7βand FASN,and antagonizes FBXW7β’s activity by enhancing FBXW7βautoubiquitination and degradation,which in turn prevents FBXW7β-mediated FASN ubiquitination and degradation,thereby regulating lipogenesis *** CSN6 and FASN are positively correlated in CRC,and CSN6-FASN axis,regulated by EGF,is responsible for poor prognosis of *** EGF-CSN6-FASN axis promotes tumor growth and implies a treatment strategy of combination of orlistat and ***-derived xenograft experiments prove the effectiveness of employing orlistat and cetuximab combination in suppressing tumor growth for CSN6/FASN-high ***,CSN6-FASN axis reprograms lipogenesis to promote tumor growth and is a target for cancer intervening strategy in CRC.

关键词： FBXW7 sustained FASN

巧妙运用变性淀粉推动烘焙食品行业可持续发展的路径探索

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

食品工程 2021年第1期 5-6,41页

作者：林俊忠中山市技师学院广东中山528400

淀粉是烘焙食品加工的主要原料,因其具有吸水膨胀等特性,可增加烘焙食品的含水量。但由于原生淀粉口感和稳定性较差,变性淀粉更多地被用于烘焙食品中,极大地改善了烘焙食品的口感和品质。基于此,介绍了变性淀粉的类型及其在烘焙食品中... 详细信息

淀粉是烘焙食品加工的主要原料,因其具有吸水膨胀等特性,可增加烘焙食品的含水量。但由于原生淀粉口感和稳定性较差,变性淀粉更多地被用于烘焙食品中,极大地改善了烘焙食品的口感和品质。基于此,介绍了变性淀粉的类型及其在烘焙食品中的应用现状,并提出了变性淀粉在烘焙食品中的发展策略。

关键词：变性淀粉烘焙食品可持续发展策略

Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver-only metastases: the clinical outcome of an open-label cohort study

在线全文

学校读者我要写书评

暂无评论

Bevacizumab with preoperative chemotherapy versus preoperati...

Methionine Deficiency Facilitates Antitumor Immunity by Altering m6A Methylation of Immune Checkpoint Transcripts

第八届中国肿瘤学术大会暨第十三届海峡两岸肿瘤学术会议

作者： Zhenhai Lu Fulong Wang Jianhong Peng Yunfei Yuan Wu Jiang Yuhong Li Xiaojun Wu Gong Chen Peirong Ding Liren Li lingheng Kong junzhong lin Rongxin Zhang Desen Wan Zhizhong Pan Department of Colorectal Surgery Sun Yat-sen University Cancer Center Department of Hepatobiliary Surgery Sun Yat-sen University Cancer Center Department of Medical Oncology Sun Yat-sen University Cancer Center

＜正＞Objective Bevacizumab as a humanized monoclonal antibody increases survival when combined with chemotherapy in first-line treatment of metastatic colorectal cancer（mCRC）.This study was conducted to assess the ...

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Methionine Deficiency Facilitates Antitumor Immunity by Alte...

KRAS基因突变预测结直肠癌单纯肝转移肝切除术后预后的价值

2022CCTB中国肿瘤标志物学术大会暨中国整合肿瘤学大会暨第十六届肿瘤标志物青年科学家论坛暨中国肿瘤标志物产业创新大会

作者： Ting Li Tan Yue-Tao Yan-Xing Chen Xiao-Jun Zheng Wen Wang Kun Liao Hai-Yu Mo junzhong lin Wei Yang Hai-Long Piao Rui-Hua Xu Huai-Qiang Ju Sun Yat-sen University Cancer Center Department of Gastroenterology and Urology Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of MedicineCentral South University Research Department of Medical Sciences Guangdong Provincial People's HospitalGuangdong Academy of Medical Sciences CAS Key Laboratory of Separation Science for Analytical Chemistry Dalian Institute of Chemical PhysicsChinese Academy of Sciences Department of Colorectal Surgery Sun Yat-sen University Cancer Center Guangdong Provincial Key Laboratory of Molecular Oncologic Pathology Southern Medical University Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer Chinese Academy of Medical Sciences

Objective:Methionine metabolism is involved in a myriad of cellular functions,including methylation reactions and redox ***,it remains unclear whether methionine metabolism,RNA methylation and antitumor immunity are molecularly ***:The antitumor immunity effect of methionine-restricted diet(MRD) feeding was assessed in murine *** mechanisms of methionine and YTH domain-containing family protein 1(YTHDF1) in tumor immune escape were determined in vitro and in ***,the MRD or YTHDF1 depletion synergizes with PD-1 blockade used to block tumor ***:We found that dietary methionine restriction reduced tumor growth and enhanced antitumor immunity by increasing the number and cytotoxicity of tumor-infiltrating CD8+ T cells in different mouse ***,the S-adenosylmethionine derived from methionine metabolism promoted the N6-methyladenosine(m6A) methylation and translation of immune checkpoints,including PD-L1 and VISTA,in tumor ***,a methionine-restricted diet or m6A-specific binding protein YTHDF1 depletion inhibited tumor growth by restoring the infiltration of CD8+ T cells,and synergized with PD-1blockade for better tumor ***,YTHDF1 expression correlated with poor prognosis and immunotherapy outcomes for cancer ***:Methionine and YTHDF1 play a critical role in anticancer immunity through regulating the functions of T *** methionine metabolism or YTHDF1 could be a potential new strategy for cancer immunotherapy.

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

中华消化外科杂志 2018年第4期17卷 393-399页

作者：彭健宏林俊忠赵玉洁邓宇翔隋峭崎潘志忠中山大学肿瘤防治中心结直肠外科华南肿瘤学国家重点实验室肿瘤医学协同创新中心广州510060

目的：探讨KRAS基因突变预测结直肠癌单纯肝转移肝切除术后预后的价值。方法：采用回顾性病例对照研究方法。收集2010年10月至2016年10月中山大学肿瘤防治中心收治的79例结直肠癌单纯肝转移行肝切除术患者的临床病理资料。采用荧光定量... 详细信息

目的：探讨KRAS基因突变预测结直肠癌单纯肝转移肝切除术后预后的价值。方法：采用回顾性病例对照研究方法。收集2010年10月至2016年10月中山大学肿瘤防治中心收治的79例结直肠癌单纯肝转移行肝切除术患者的临床病理资料。采用荧光定量聚合酶链反应仪和激光飞行质谱仪检测结直肠癌手术切除标本肿瘤组织KRAS基因突变情况。观察指标：（1）KRAS基因突变情况。（2）KRAS突变状态与结直肠癌单纯肝转移患者临床病理因素的关系。（3）随访和生存情况。采用门诊和电话方式进行随访，了解患者肿瘤无复发生存情况和总体生存情况。随访时间截至2017年6月30日。KRAS基因突变状态与结直肠癌单纯肝转移患者临床病理因素的关系分析采用x2检验或Fisher确切概率法。采用Kaplan-Meier法绘制生存曲线并计算生存时间，采用COX回归模型进行生存分析。结果：（1）KRAS基因突变情况：79例结直肠癌手术切除标本肿瘤组织中，KRAS基因野生型54例，KRAS基因突变型25例。25例KRAS基因突变型患者中，21例第2号外显子12号密码子突变，突变类型为GGT〉GAT（G12D）13例、GGT〉GTT（G12V）4例、GGT〉TGT（G12C）2例、GGT〉GCT（G12A）1例、GGT〉CGT（G12R）1例；3例第2号外显子13号密码子突变，突变类型均为GGC〉GAC（G13D）；1例第3号外显子61号密码子突变，突变类型为CAA〉CAT （Q61H）。（2）KRAS突变状态与结直肠癌单纯肝转移患者临床病理因素的关系：KRAS基因突变型结直肠癌单纯肝转移患者原发肿瘤部位分别为右半结肠11例、左半结直肠14例，KRAS基因野生型患者原发肿瘤部位为右半结肠7例、左半结直肠47例，两者比较，差异有统计学意义（χ^2=9.357，P〈0.05）。（3）随访和生存情况：79例患者均获得随访，随访时间为2.0-71.0个月，中位随访时间为29.0个月。25例KRAS基因突变型患者中位肿瘤无复发生存时间和中位总体生存时间分别为11.3个月和43.5个月，54例KRAS基因野生型患者分别为9.9个月和44.3个月，两者肿瘤无复发和总体生存情况比较，差异均无统计学意义［风险比（HR）=1.255,1.108，95%可信区间：0.741-2.126，0.521-2.355，P〉0.05］。进一步分析结果显示：美国纪念斯隆凯特琳癌症中心（MSKCC）预后风险评分（CRS）低危患者中，17例KRAS基因突变型患者中位肿瘤无复发生存时间为11.3个月，26例KRAS基因野生型患者为23.5个月，两者肿瘤无复发生存情况比较，差异有统计学意义（HR=2.082，95%可信区间：1.006-4.307，P〈0.05）；17例KRAS基因突变型患者中位总体生存时间为44.6个月，26例KRAS基因野生型患者为49.0个月，两者总体生存情况比较，差异无统计学意义（HR=1.165，95%可信区间：0.413-3.282，P〉0.05）。MSKCC CRS高危患者中，7例KRAS基因突变型患者中位肿瘤无复发生存时间和中位总体生存时间分别为5.6个月和28.7个月，24例KRAS基因野生型患者分别为4.5个月和36.7个月，两者肿瘤无复发和总体生存情况比较，差异均无统计学意义（HR=0.402，1.197，95%可信区间：0.284-1.656，0.371-3.866，P〉0.05）。结论：KRAS基因突变多发生在右半结肠癌。KRAS基因突变MSKCC CRS低危患者肿瘤无复发生存时间显著缩短。

关键词：结肠肿瘤直肠肿瘤肝转移转化医学 KRAS基因基因突变外科手术预后